EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 13 January 2022

Safeguarding the supply of medicines to patients in Europe

By Lars Fruergaard Jørgensen

"I am proud to say that despite an exponential increase in the demand for some medicines, the research-based pharmaceutical industry was able to increase capacity, in some cases by as much as 300-400 percent, and manage supply issues to the point that not a single EFPIA member reported disruption to supply of finished products during that extremely challenging period."

Lars Fruergaard Jørgensen, President and CEO at Novo Nordisk and First Vice-President at EFPIA, reflects on what Covid-19 thought us and what we can do to avoid shortages of medicines in the future.

Read more

News

EFPIA statement on a GDPR Code of Conduct
13 January 2022

A GDPR Code of conduct will enable the sector to align on key data protection positions, thereby providing more consistency,... Read more

Stronger Intellectual Property Rights in EU Free Trade Agreements can boost GDP, productivity,...
11 January 2022

Discover a recent ECIPE report, supported by EFPIA among other industry associations. Read more

EFPIA publishes the Evidence MIX (Measures, Insights and eXamples) Report
06 January 2022

Evaluating the EU Regulatory System, Assessing the Environment, Gaining Direct Experimental Insights, and Offering Policy... Read more

EFPIA Press Release welcoming the French Presidency of the Council of the EU
04 January 2022

As the French Presidency of the Council begins, it is time for Europe to back innovation and boost access to medicines.... Read more

Industry response to the Northern Ireland Protocol proposals
17 December 2021

The European Commission and UK Government have taken significant practical steps towards resolving outstanding issues... Read more

Events

Supporting Pharma Innovation in Europe
24 January 2022 (Virtual event)

Presented by the FT, in partnership with EFPIA. Read more

Introducing the Innovative Health Initiative: Europe’s new partnership for health
26 January 2022 (Virtual event)

Registration is now open! Read more

What we are reading

Innovation and access: Improving Europe’s pharmaceutical regulatory framework
On 13 January 2022 (pharmaphorum.com)

EMA “lags behind” other international regulators when it comes to approval timelines, finds EFPIA analysis. Read more

Leaders of change: does it take a patient to put patients first?
On 01 January 2022 (The Lancet)

Policy makers with a personal or heightened understanding of the ravages of cancer often have greater empathy with the... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Leopold Plaza Building
Rue du Trône 108
B-1050 Brussels (Belgium)

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu